Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202932 | 0.90 | SMN1; SMN2 (0.47) | SMN1; SMN2TP53KMT2ARAB9ANPC1 | |
| SCHEMBL357809 | 0.82 | TTR (0.44) | SMN1; SMN2TP53KMT2ARAB9ANPC1 | |
| SCHEMBL15327654 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2TP53KMT2ARAB9AMEN1 | |
| SCHEMBL2200779 | 0.81 | KMT2A (0.46) | SMN1; SMN2TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL2208219 | 0.81 | KMT2A (0.47) | SMN1; SMN2TP53KMT2ARAB9AMEN1 | |
| SCHEMBL2205960 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2TP53KMT2ARAB9AMEN1 | |
| SCHEMBL358004 | 0.80 | NOTUM (0.43) | SMN1; SMN2TP53KMT2AALDH1A1NOTUM | |
| SCHEMBL356937 | 0.80 | NOTUM (0.43) | SMN1; SMN2KMT2AMEN1NOTUM | |
| SCHEMBL4321362 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2TP53KMT2ARAB9AMEN1 | |
| SCHEMBL4324303 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53KMT2ARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205573-B1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | claimed |
| EP-2205573-B1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-7981914-B2 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | AR, NAT1, TBXA2R | SMN1; SMN2 1615/4885TP53 3030/4885KMT2A 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.